Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S NVO ... 3 trial results for its cocktail obesity drug, CagriSema. Results showed a weight loss of 22.7% ...

Both CagriSema and retatrutide are set to seek regulatory approval in the first quarter of 2026. Price cuts in the most popular weight-loss drug Despite recent setbacks, Novo Nordisk’s latest ...

A series of disappointing trial results for Novo Nordisk’s next-generation weight-loss drugs has exacerbated investor concerns about its competitiveness. In December 2024, the company announced phase ...

a similar mechanism of action ("MoA') to the wildly successful drugs Zepbound and Wegovy, marketed and sold by Novo Nordisk and Eli Lilly (LLY) respectively, which are expected to drive an obesity ...

Danish drugmaker Novo Nordisk has been dethroned by German software ... Much of the damage was done in December when the stock tanked after CagriSema, Novo’s experimental anti-obesity drug ...

Copenhagen, DENMARK — Novo Nordisk defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss ...

In its search for its next-generation obesity drug, Novo Nordisk on Friday put $1 billion on the line ... Novo is not new to non-incretin development. CagriSema, which the pharma had been positioning ...

Novo Nordisk's financial results have not quite met the market's expectations. The company also suffered from a clinical setback that sank its stock price. However, the stock now looks reasonably ...